Skip to content
PoliticalRepoPoliticalRepo

Person

Official portrait of Sen. Banks, Jim [R-IN]

Sen. Banks, Jim [R-IN]

United States · Official source

Records

1,648 records where Sen. Banks, Jim [R-IN] is listed as a sponsor, author, or other actor. Search with topics and years

Bill· SS. 4627 (119th)referred

FARM AI Act of 2026

United States · United States Congress · 21 May 2026

Bill· SS. 4501 (119th)referred

BACK OFF Act

United States · United States Congress · 12 May 2026

Bill· SS. 4487 (119th)referred

Veterans’ Compensation Cost-of-Living Adjustment Act of 2026

United States · United States Congress · 11 May 2026

Veterans' Compensation Cost-of-Living Adjustment Act of 2026 This bill requires the Department of Veterans Affairs (VA) to increase the amounts payable for wartime disability compensation, additional compensation for dependents, the clothing allowance for certain disabled veterans, and dependency and indemnity compensation for surviving spouses and children. Specifically, the VA must increase the amounts by the same percentage as the cost-of-living increase in benefits for Social Security recipients that is effective on December 1, 2026. The act requires the VA to publish the amounts payable, as increased, in the Federal Register. The VA is authorized to make a similar adjustment to the rates of disability compensation payable to persons who have not received compensation for service-connected disability or death.

Bill· SS. 4472 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 30 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the bill revises the NIH grants to require (1) the NIH, in considering grant renewal, to assess available information on the safety and efficacy of the investigational drugs; (2) grantees to promptly report available safety data from ongoing clinical trials; and (3) the NIH to determine the timeframe for enrollment in clinical trials for the investigational drugs. Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases. Each plan must include the FDA's previous actions and recommendations for improvements. Finally, the Government Accountability Office and the Department of Health and Human Services must report on the impacts of these grants. 

Bill· SS. 4456 (119th)referred

AI OVERWATCH Act

United States · United States Congress · 30 April 2026

Bill· SS. 4467 (119th)referred

Ensuring Seniors’ Access to Quality Care Act

United States · United States Congress · 30 April 2026

Ensuring Seniors' Access to Quality Care Act This bill repeals certain restrictions under Medicare and Medicaid that prohibit the approval of nurse-aide training and competency evaluation programs in skilled nursing facilities that have been subject to specified regulatory actions (e.g., civil penalties) for substandard quality of care. The Centers for Medicare & Medicaid Services (CMS) must still disapprove such programs for up to two years; however, the CMS must rescind the disapproval upon completion of corrective action and may require additional oversight of the program for purposes of rescission. The bill also allows Medicaid and Medicare providers (e.g., skilled nursing facilities) to access, through the National Practitioner Data Bank, disciplinary information for affiliated physicians and other health care practitioners, as reported by state licensing authorities.

Bill· SS. 4409 (119th)referred

START Act

United States · United States Congress · 28 April 2026

Bill· SS. 4360 (119th)referred

INSIGHT Act

United States · United States Congress · 21 April 2026

Bill· SS. 4348 (119th)referred

PARITY Act

United States · United States Congress · 20 April 2026

Bill· SS. 4189 (119th)open

INSULIN Act of 2026

United States · United States Congress · 25 March 2026

Bill· SS. 4156 (119th)referred

GAMES Act

United States · United States Congress · 19 March 2026

Bill· SS. 4061 (119th)referred

RAYS Act

United States · United States Congress · 11 March 2026

Resolution· SRESS.Res. 622 (119th)passed

A resolution expressing support for the designation of February 21 through February 28, 2026, as "National FFA Week", recognizing the important role of the National FFA Organization in developing the next generation of globally conscious leaders who will change the world, and celebrating the 50th anniversary of the chartering of the State of Alaska as a State FFA Association.

United States · United States Congress · 26 February 2026

This resolution supports the designation of February 21-28, 2026, as National FFA (Future Farmers of America) Week. It also celebrates the 50th anniversary of the chartering of Alaska as a State FFA Association of the National FFA Organization.

Bill· SS. 3917 (119th)referred

The Dalilah Law

United States · United States Congress · 25 February 2026

Bill· SS. 3794 (119th)open

SAFE Drugs Act of 2026

United States · United States Congress · 5 February 2026

Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2026 or the SAFE Drugs Act of 2026 This bill provides for increased oversight of drug compounding and imposes statutory limits on compounded drugs that are essentially copies of commercially available drugs. Currently, subject to certain requirements, compounded drugs (i.e., drugs that are mixed or altered to meet patient needs) do not require Food and Drug Administration (FDA) approval. Additional limits apply to the compounding of drugs that are essentially copies of commercially available drug products. Under the bill, a compounded drug is essentially a copy of a commercially available drug product if (1) the compounded drug contains any active ingredient found in a commercially available drug product, and (2) there is no change made for an individual patient that results in a significant difference between the compounded drug and the commercially available drug. (The FDA’s current definition of the term also addresses dosage strength and route of administration.)  The bill increases the frequency at which a licensed pharmacist or physician may compound a drug that is essentially a copy of a commercially available drug to 20 times per month. Current FDA policy allows four such prescriptions per month. The bill also imposes annual reporting requirements on physicians, facilities, and pharmacies (except hospital-based pharmacies) that compound certain drug products for out-of-state patients more than 20 times per month. Further, the bill subjects certain large-scale outsourcing facilities (i.e., FDA-registered facilities that compound in bulk) to regular inspection and reporting requirements.

Bill· SS. 3747 (119th)open

Home School Graduation Recognition Act

United States · United States Congress · 29 January 2026

Home School Graduation Recognition Act This bill clarifies that students who complete their secondary education in a home school setting recognized under state law are high school graduates for purposes of eligibility for federal student aid.

Bill· SS. 3752 (119th)referred

SAVE America Act

United States · United States Congress · 29 January 2026

Safeguard American Voter Eligibility Act or the SAVE America Act This bill requires individuals to provide documentary proof of U.S. citizenship when registering to vote, and requires photo identification to vote, in federal elections. Specifically, the bill prohibits states from accepting and processing an application to register to vote in a federal election unless the applicant presents documentary proof of U.S. citizenship. The bill specifies what documents are considered acceptable proof of U.S. citizenship, such as identification that complies with the REAL ID Act of 2005 that indicates U.S. citizenship. Further, the bill (1) prohibits states from registering an individual to vote in a federal election unless, at the time the individual applies to register to vote, the individual provides documentary proof of U.S. citizenship; and (2) requires states to establish an alternative process to demonstrate U.S. citizenship. Each state must take affirmative steps on an ongoing basis to ensure that only U.S. citizens are registered to vote, which shall include establishing a program to identify individuals who are not U.S. citizens using information supplied by certain sources. Additionally, states must remove noncitizens from their official lists of eligible voters. The bill (1) provides for a private right of action for certain violations, and (2) establishes criminal penalties for certain offenses. Individuals voting in federal elections must present an eligible photo identification document. An individual who votes by absentee ballot must submit a copy of their identification document with both the request for, and the submission of, the absentee ballot.